Compounding Pharmacy Fraud: Referrals, Ingredients and Reimbursement-Driven Claims

Compounding pharmacy fraud turns paid referrals, inflated ingredient prices or false patient-payment records into prescription claims that draw money from health care programs at taxpayers’ expense. The formula, the referral agreement and the billing screen can each show a different part of the same arrangement. A pharmacist may know why an ingredient entered the formula. A marketer may know who paid for the prescription. A reimbursement employee may know what the pharmacy told the payer. Connecting those decisions is how we get from a suspicious prescription to the business behind it.

How Paid Referrals Become Pharmacy Claims

A compounding referral scheme connects the source of the prescription to the pharmacy’s expected reimbursement. Recruitment, prescriber payments, formula selection and copay funding can all serve that same sale.

The FDA’s compounding framework distinguishes traditional patient-specific preparation from registered outsourcing facilities. For a pharmacy claim, the question is what the prescription supports and what the pharmacy told the payer.

In its Fagron settlement announcement, the Justice Department alleged that pharmacy subsidiary Pharmacy Services Inc. paid physicians through bogus consulting agreements, used sham insurance programs to manipulate pricing, submitted fraudulent compound claims and improperly waived copays. The same resolution covered allegations that Freedom Pharmaceuticals supplied inflated ingredient benchmarks. The Defense Criminal Investigative Service provided investigative support in the Fagron case.

How Did Prescription Pads Drive Reimbursement?

Prescription pads can steer formula choices toward what an insurer will reimburse. In its account of the pharmacy owner’s guilty plea, the Justice Department described reimbursement-driven prescription pads at Fusion Rx.

In its corporate guilty plea, Fusion Rx admitted a scheme involving pharmacy-funded apparent copayments and claims premised on collection of those payments. The plea identified TRICARE, Medicare, the federal employee health benefit program, Amtrak and private plans.

For an employee who handled those transactions, the useful detail may be who supplied the pad, who chose the formula or who funded the amount recorded as the patient’s payment. We connect those decisions to the claim. The payment entry matters because of what it told the payer.

Ingredient Prices Can Sell the Formula

Average wholesale price is a reimbursement benchmark. AWP and the actual purchase price occupy different places in the calculation: the supplier’s invoice shows what the pharmacy paid, while the payer’s formula determines how the benchmark affects reimbursement. The usual-and-customary cash charge is another amount, defined by the payer’s rules.

In its 2021 complaint announcement concerning Professional Compounding Centers of America, the Justice Department alleged that the ingredient supplier marketed inflated AWPs, the profit they could generate and formulas containing high-AWP ingredients to its pharmacy customers. PCCA allegedly used the expected reimbursement to sell the ingredients that would produce it.

The department explained the payment connection: TRICARE based compound reimbursement in part on the reported AWP of each ingredient. It alleged that PCCA’s prices and marketing caused pharmacies to submit inflated claims. The formula itself was part of the sales pitch. The Defense Criminal Investigative Service and FBI assisted the investigation.

We see the absurdity in that allegation. The money available from the prescription was helping sell what went into it. A person working at the compounding bench or in purchasing may recognize the ingredient choice long before seeing the supplier’s pricing reports.

Medisca’s Prices at Each Step

The government’s allegations in Medisca’s settlement agreement put the prices side by side. Medisca allegedly acquired mometasone furoate for under $8 per gram, sold it to compounding pharmacies for over $1,000 per gram and established an AWP above $7,300 per gram.

One ingredient. Three very different prices.

The government alleged that Medisca deliberately created the gap to induce pharmacies to buy its ingredients, knowing that the larger gap offered its customers more profit from federal healthcare reimbursement. The allegations concerned claims to TRICARE and the Department of Labor’s workers’ compensation program. Medisca agreed to a $21.75 million civil settlement in 2024 over the alleged pricing scheme.

For the pharmacy side of that story, who selected the formula, who received the pricing pitch and who approved the claim are separate questions. Supplier records show how the ingredient was sold. Pharmacy records show how that sale became a prescription and a request for payment.

What an Insider Can Connect

The strongest account follows a particular prescription through the business. It connects what was ordered, what was prepared, what the payer was told and where the money went. Different employees can supply different parts of that account.

The Prescription and Formula

A pharmacist or technician who knows why the formula changed can explain the difference between what the prescriber ordered and what the pharmacy prepared. Supplier marketing can show why a particular ingredient was promoted inside the business.

The Referral and Its Payment

A marketing employee may understand the arrangement that a billing employee sees only as another order. The promised service, the payment and the prescription help us distinguish the participants’ decisions.

The Dispense and the Claim History

New York’s NYRx pharmacy policy makes the distinction explicit: submitting a claim does not prove that the prescription was furnished. An employee who handled dispensing or billing can explain what happened to the medication and whether a rejected submission was corrected and resubmitted or an accepted claim was reversed or adjusted.

Patient Care America and Referral Financing

Patient Care America and private-equity firm Riordan, Lewis & Haden agreed to a joint $21.05 million civil payment in the September 2019 resolution. The Justice Department alleged that the pharmacy paid marketers targeting military families, financed physician referrals, selected high-reimbursement compounds and disguised copayment funding through a charity associated with a marketer.

The government’s account identified the investment firm’s alleged knowledge, management and financing of the arrangement. That makes the approval and funding decisions part of the pharmacy story. The people directing the business could matter alongside the people dispensing the medicine.

The whistleblowers’ complaint identified a marketing director and a reimbursement services manager who had also worked as an IV lead technician. Their work exposed different parts of the same business: the arrangements generating prescriptions and the work obtaining payment. Those roles show why an employee’s explanation can connect records that otherwise sit in separate departments.

Compounding Pharmacy Whistleblower Cases

A compounding pharmacy whistleblower can bring knowledge from purchasing, dispensing, marketing or reimbursement. The PCCA case began with a whistleblower who had been a part owner and pharmacist at a pharmacy that bought its ingredients. The government joined that case.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why That Formula Was Chosen

If you know who paid for the referrals, chose the ingredients or supplied the apparent copayments, speak with our whistleblower experts about your compounding pharmacy case. We work beside you to build your strongest compounding pharmacy whistleblower case and bring in pharmacy fraud whistleblower lawyers who understand compound claims and referral arrangements. You bring the view from inside the pharmacy; we bring the expertise and partnership to pursue it with you.